Background: The aim of this study was to record and assess the efficacy and safety ofthromboprophylaxis with an intermediate dose of Tinzaparin in lung cancer patients with high thrombotic risk. Methods: This was a non-interventional, single-arm, prospective cohort study of lung cancer patients who received thromboprophylaxis with Tinzaparin 10.000 Anti-Xa IU in 0.5 mL, OD, used in current clinical practice. Enrolled ambulatory patients signed informed consent. Anti-Xa levels were tested. Results: In total, 140 patients were included in the study, of which 81.4% were males. The histology of the tumor was mainly adenocarcinoma. Lung cancer patients with high thrombotic risk based on tumor, patient, treatment, and laboratory-related factors were enrolled. Only one patient experienced a thrombotic event (0.7%), and 10 patients had bleeding events (7.1%), including only one major event. Anti-Xa levels measured at 10 days and 3 months did not differ significantly between patients who developed hemorrhagic events and those who did not (p= 0.26 andp= 0.32, respectively). Conclusion: Thromboprophylaxis with an intermediate Tinzaparin dose in high thrombotic-risk lung cancer patients is a safe and effective choice for the prevention of VTE.
背景：本研究旨在记录并评估中等剂量亭扎肝素用于高血栓风险肺癌患者血栓预防的有效性和安全性。方法：本研究为一项非干预性、单臂、前瞻性队列研究，纳入在现行临床实践中接受亭扎肝素（10,000抗Xa IU/0.5 mL，每日一次）血栓预防的肺癌患者。所有入组的门诊患者均签署知情同意书。研究检测了抗Xa因子水平。结果：研究共纳入140例患者，其中81.4%为男性。肿瘤组织学类型以腺癌为主。入组患者均为基于肿瘤因素、患者因素、治疗因素及实验室相关因素评估为高血栓风险的肺癌患者。仅1例患者发生血栓事件（0.7%），10例患者发生出血事件（7.1%），其中仅1例为严重出血事件。发生出血事件与未发生出血事件的患者在治疗10天及3个月时检测的抗Xa因子水平无显著差异（p值分别为0.26和0.32）。结论：对于高血栓风险的肺癌患者，采用中等剂量亭扎肝素进行血栓预防是一种安全有效的静脉血栓栓塞症预防方案。
肿瘤(癌症)患者之家